Pharmaceutical Report Library l Report Store l Pharma Intelligence

Q4 2016 Outlook Report

In this report, we cover catalysts from 23 drugs, devices and diagnostics expected to occur in Q4 2016. We have also included a list of Large Impact catalysts in the drug and device/diagnostic areas through Q4 2016.

November 16, 2016

Find out more

Indonesia Regulatory Issues

$2,995.00

Challenges for foreign pharma companies in relation to Indonesia’s pharma system include lengthy and variable approval periods, compulsory licenses, and counterfeits.

November 2, 2016

Find out more

Seviprotimut-L

Seviprotimut-L (Polynoma/CK Life Sciences) is a polyvalent, shed-antigen vaccine in development for the adjuvant treatment of Stage IIb–III melanoma patients. Seviprotimut-L contains a combination of antigens from three proprietary melanoma cell lines, and is intended to stimulate the body’s immune system to fight cancer.

May 23, 2018

Find out more

Tenelia

Tenelia (teneligliptin; Mitsubishi Tanabe) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut.

November 7, 2017

Find out more

Drug Delivery: Injection Devices

$4,750.00

Despite its relative invasiveness and technological maturity, instrument-based injection of pharmaceutical preparations is regarded as one of the most accurate, effective, reliable, and reproducible methods of therapeutic drug and fluid delivery.

December 17, 2019

Find out more

Treatment of VTE – US KOL Interview

$599.00

This interview with a US hematologist focuses on the changing dynamics with the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.

November 2, 2015

Find out more

Nucala

Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, and differentiation of eosinophils.

July 31, 2018

Find out more

Disease Analysis: Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.

February 24, 2022

Find out more

Yescarta

Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained US approval for relapsed/refractory patients in October 2017.

January 30, 2019

Find out more

Big Pharma Diversification Strategies

$2,995.00

Pressures ranging from continually declining revenues as a result of generics and impending biosimilars launches, to slow R&D productivity and market access restrictions could cause the Big Pharma peer set to evaluate business opportunities beyond pharmaceuticals.

March 4, 2018

Find out more

Idelvion

Idelvion is a long-acting recombinant factor IX (rfIX) therapy developed by CSL Behring for hemophilia B. Idelvion is produced through the fusion of rfIX, manufactured in Chinese hamster ovary cells, to human recombinant albumin via a cleavable linker.

May 4, 2018

Find out more

Market Spotlight: Osteoarthritis and Osteoarthritis Pain

$1,318.00

This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

March 4, 2022

Find out more

Global Markets for Infection Control and Biosafety Products, October 2016

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global medical waste disposal, device reprocessing, standard and safety needle/syringe, sharps disposal, and sterilization equipment and services markets.

October 7, 2016

Find out more

Respiratory Care: Noninvasive Ventilation and Airway Management Products

$4,750.00

Asthma and COPD, the two most prevalent respiratory diseases, affect nearly 600 million people worldwide, with annual mortality rates exceeding 3 million for COPD and 400,000 for asthma. COVID-19 has infected more than 60 million people worldwide, resulting in 1.5 million deaths. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the positive airway pressure (PAP)-based noninvasive ventilation (NIV) and airway management products market, including CPAP and BiPAP devices as well as heat/moisture exchangers (HMEs), humidifiers, and nebulizers (including large- and small-volume nebulizers and nebulizer compressors).

December 17, 2020

Find out more

Catch Up On CAR-T

$699.00

Sale!

With the approval of the first CAR-T therapies – Novartis’ Kymriah and Gilead/Kite’s Yescarta – what had been the promise of cutting-edge science is now reality.

November 24, 2017

Find out more

Report library

Q4 2016 Outlook Report

Indonesia Regulatory Issues

Seviprotimut-L

Tenelia

Drug Delivery: Injection Devices

Treatment of VTE – US KOL Interview

Nucala

Disease Analysis: Triple-Negative Breast Cancer

Yescarta

Big Pharma Diversification Strategies

Idelvion

Market Spotlight: Osteoarthritis and Osteoarthritis Pain

Global Markets for Infection Control and Biosafety Products, October 2016

Respiratory Care: Noninvasive Ventilation and Airway Management Products

Catch Up On CAR-T